Unknown

Dataset Information

0

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.


ABSTRACT: BACKGROUND:Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To date, no blood biomarkers have been identified in NSCLC to predict clinical outcomes of treatment with anti-PD-1 antibodies. PATIENT AND METHODS:We performed an analysis of retrospectively registered data of 157 patients with advanced NSCLC treated with anti-PD-1 antibodies at Mayo Clinic in Florida and Rochester. White blood cell count, absolute neutrophil count (ANC), absolute lymphocyte count (ALC), ANC to ALC (ANC: ALC) ratio, absolute eosinophil count, absolute monocyte count (AMC), platelet counts, and myeloid to lymphoid (M:L) ratio at baseline and throughout treatment were assessed. Kaplan-Meier method and Cox proportional hazards model were performed. RESULTS:We treated 146 patients with nivolumab and 11 with pembrolizumab between January 1, 2015 and April 15, 2017. At median follow-up of 20?months, median OS and PFS were 6.0 and 2.6?months, respectively. Higher baseline ANC, AMC, ANC: ALC ratio and M: L ratio correlated with worse clinical outcomes in patients who underwent anti-PD-1 treatment. A baseline ANC: ALC ratio of 5.9 or higher had a significantly increased risk of death (hazard ratio [HR] =1.94; 95% confidence interval [CI], 1.24-3.03; P?=?0.004) and disease progression (HR, 1.65; 95% CI, 1.17-2.34; P?=?0.005) compared with patients with lower ratio. Similarly, a baseline M: L ratio of 11.3 or higher had significantly increased risk of death (HR, 2.5; 95% CI, 1.54-4.05; P?

SUBMITTER: Soyano AE 

PROVIDER: S-EPMC6251165 | biostudies-literature | 2018 Nov

REPOSITORIES: biostudies-literature

altmetric image

Publications

Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies.

Soyano Aixa E AE   Dholaria Bhagirathbhai B   Marin-Acevedo Julian A JA   Diehl Nancy N   Hodge David D   Luo Yan Y   Manochakian Rami R   Chumsri Saranya S   Adjei Alex A   Knutson Keith L KL   Lou Yanyan Y  

Journal for immunotherapy of cancer 20181123 1


<h4>Background</h4>Anti-programmed cell death 1 (PD-1) antibodies have demonstrated improved overall survival (OS) and progression-free survival (PFS) in a subset of patients with metastatic or locally advanced non-small cell lung cancer (NSCLC). To date, no blood biomarkers have been identified in NSCLC to predict clinical outcomes of treatment with anti-PD-1 antibodies.<h4>Patient and methods</h4>We performed an analysis of retrospectively registered data of 157 patients with advanced NSCLC tr  ...[more]

Similar Datasets

| S-EPMC6439838 | biostudies-literature
| S-EPMC8277895 | biostudies-literature
| S-EPMC7086375 | biostudies-literature
| S-EPMC5800935 | biostudies-literature
| S-EPMC8563162 | biostudies-literature
| S-EPMC7774722 | biostudies-literature
| S-EPMC5770142 | biostudies-literature
| S-EPMC7413896 | biostudies-literature
| S-EPMC8667098 | biostudies-literature
| S-EPMC7270107 | biostudies-literature